NCT03915444进行中（未招募）2 期
A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
HonorHealth Research Institute4 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2019年7月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 42
- 试验地点
- 4
- 主要终点
- 12- Month Overall Survival
研究概览
简要总结
This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
详细描述
This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
An individual cycle of therapy will be defined as Days 1 and 8 every 21 days. Multiple cycles may be administered until the patient is withdrawn from therapy.
Overall response rates as well as individual categories of response (CR, PR, SD, and PD) will be determined using RECIST 1.1 (Frese 2012). Time-to-event endpoints, including PFS and OS will be assessed using the Kaplan-Meier method (Kaplan 1958). Evaluation of stable disease at 9 weeks will also be assessed. Toxicity (adverse events) will be recorded using the NCI CTCAE, version 5.0.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 105 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years of age; male or female
- •Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.
- •Capable of providing informed consent and complying with trial procedures.
- •Karnofsky Performance Status (KPS) of ≥ 70%.
- •Life expectancy ≥ 12 weeks.
- •Measurable tumor lesions according to RECIST 1.1 criteria.
- •< Grade 2 pre-existing peripheral neuropathy per NCI CTCAE, Version 5.0
- •Patient has acceptable coagulation status as indicated by an INR ≤1.5 x ULN. Patients on anticoagulation can be included at the discretion of the investigator.
- •Patients must have normal organ and marrow function as defined below:
- •Absolute neutrophil count ≥1,500/mm3
- •Platelet concentration ≥100,000/mm3 with no platelet transfusions within 7 days prior to laboratory sample
- •Hemoglobin > 9.0g/dL
- •Hematocrit level > 27%
- •Total bilirubin within 1.25 times institutional upper limit of normal (ULN)
- •Alanine aminotransferase (ALT) and AST < 10 × institutional ULN
- •Serum creatinine <1.5 mg/dl
- •Females of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must:
- •Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting IP therapy (including dose interruptions), and while on study medication or for a longer period if required by local regulations following the last dose of IP; and
- •Have a negative serum pregnancy test (β -hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study therapy. This applies even if the subject practices true abstinence* from heterosexual contact.
- •Male subjects must practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following discontinuation from study treatment, even if he has undergone a successful vasectomy.
排除标准
- •Patients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. Prior treatments in the neoadjuvant and/or adjuvant setting with gemcitabine and/or 5-FU based therapies or gemcitabine and/or 5FU administered as a radiation sensitizer are allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present.
- •Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation of study treatment.
- •Exposure to any investigational agent within 4 weeks prior to initiation of study treatment.
- •Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
- •History of other malignancies (except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix) unless documented free of cancer for ≥5 years.
- •Current, serious, clinically significant cardiac arrhythmias as determined by the investigator.
- •History of HIV infection.
- •Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals.
- •Major surgery within 4 weeks prior to initiation of study treatment.
- •Any condition in the opinion of the principal investigator that might interfere with the patient's participation in the study or in the evaluation of the study results.
- •Any condition in the opinion of the principal investigator that is unstable and could jeopardize the patient's participation in the study.
研究组 & 干预措施
NabCG
Experimental
nab-paclitaxel 125mg/m2 cisplatin 25 mg/m2 gemcitabine 1000 mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days
干预措施: nab-Paclitaxel + Cisplatin + Gemcitabine (Drug)
结局指标
主要结局
12- Month Overall Survival
时间窗: 360 days
Evaluate the 12-month OS rate in patients with metastatic PDA treated with nab-paclitaxel plus cisplatin plus gemcitabine
次要结局
- Pain Control: Brief Pain Inventory (BPI)(63 days)
- Change in tumor markers(63 days)
- Quality of Life: MD Anderson Symptom Inventory (MDASI-GI)(63 days)
- Potential tumor biomarkers(63 days)
- Disease Response(63 days)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
2 期
Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic CancerLocally Advanced Pancreatic CancerNCT03815461Chinese Academy of Medical Sciences60
已完成
1 期
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDAStage IV Pancreatic CancerNCT01893801Pancreatic Cancer Research Team25
Unknown
2 期
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract CancerBiliary Tract CancerNCT04692051Huazhong University of Science and Technology100
尚未招募
2 期
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.Cervical CancerNCT06426056Peking University Third Hospital64
终止
2 期
Treatment With Nab-paclitaxel in Cutaneous SCCCutaneous Squamous Cell CarcinomaNCT02076243Icahn School of Medicine at Mount Sinai2